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orchestrates a restructuring of the 
chromosome into an axial filament. 
In the formation of an axial filament 
the chromosome extends all the 
way to the cell poles and its distri-
bution in the cell narrows. It is pos-
sible that RacA both promotes the 
movement of DisA along the chro-
mosome and facilitates the detec-
tion of DNA lesions.
After the first identification of 
a checkpoint in the bacterium 
Escherichia coli (Defais et al., 1971), 
the characterization of checkpoint 
mechanisms has been largely con-
fined to eukaryotic cells. The new 
work shows that the study of check-
points in prokaryotes is far from 
exhausted. Future work may estab-
lish whether there are surveillance 
mechanisms in eukaryotes that mir-
ror the dynamic behavior of DisA in 
scanning the genome for damage.
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Absence of CYLD, which encodes a deubiquitinating enzyme, causes an inherited disease 
characterized by benign skin tumors. In this issue of Cell, Massoumi et al. (2006) show that 
CYLD deubiquitinates the coactivator Bcl-3, thereby preventing its translocation into the 
nucleus, where it normally interacts with NF-κB and activates transcription of proliferation 
genes in response to growth signals.Ubiquitin signaling regulates a 
wide variety of cellular processes, 
including degradation of proteins, 
receptor endocytosis, DNA repair, 
gene transcription, virus budding, 
the cell cycle, inflammation, and 
immune responses (Haglund and 
Dikic, 2005). Many of these func-
tions are dependent on the action of 
ubiquitin E3 ligases, which catalyze 
the transfer of ubiquitin to a protein 
substrate, leading to distinct types 
of ubiquitin modifications of target 
proteins (such as monoubiquitina-
tion and polyubiquitination). Pro-
tein ubiquitination is a reversible 
process: Ubiquitin can be cleaved 
from its protein substrates by deu-
biquitinating enzymes (DUBs), also known as deubiquitinases. Thus, 
similar to protein phosphorylation, 
regulated ubiquitination and deu-
biquitination of specific substrates 
are instrumental in cellular signaling 
in vivo (Haglund and Dikic, 2005). 
Therefore, it is not surprising that 
identification of substrates of E3 
ligases and DUBs is a key step for 
better understanding many different 
biological functions. In this issue of 
Cell, Massoumi et al. (2006) provide 
molecular insight into the function of 
the deubiquitinase CYLD.
CYLD is a tumor suppressor gene 
mutated in familial cylindromatosis, 
also called “turban tumor syndrome,” 
an autosomal-dominant condition 
that predisposes to multiple skin Cell 125tumors (Bignell et al., 2000). The gene 
product, CYLD, is a DUB recently 
implicated in modulation of the NF-
κB pathway, a crucial mediator of 
immune responses and inflammation. 
Activation of the NF-κB master tran-
scription factor is thought to occur 
via either a classical or an alternative 
pathway (Hayden and Ghosh, 2004) 
(Figure 1). The classical pathway is 
activated by a variety of inflammatory 
signals, for example TNF-α, interleu-
kin-1, and lipopolysaccharide. The 
signal triggers activation of the IKK 
(inhibitor of NF-κB kinase) complex, 
which includes IKK-α, IKK-β, and IKK-
γ (NEMO). This leads to phosphoryla-
tion, polyubiquitination, and eventu-
ally degradation of IκB protein (the , May 19, 2006 ©2006 Elsevier Inc. 643
figure 1. cYLD-Mediated Regulation of 
the nf-κB Pathway
Target proteins of CYLD differ in each signal-
ing pathway. In the classical pathway (left), 
NF-κB is activated by cytokines or viruses, 
which lead to proteasomal degradation of 
IκB-α following its phosphorylation by the 
IKK complex and Lys48-linked polyubiq-
uitination. Targets of CYLD in the classical 
pathway are TRAFs and IKK-γ. The alterna-
tive pathway (middle) is mediated by NIK and 
IKK-α, resulting in p52-REL-B complex for-
mation, which controls expression of NF-κB 
target genes. In keratinocytes (right), TPA-
induced ubiquitination of Bcl-3 is required 
for its nuclear translocation and induction 
of cyclin D1 gene expression. CYLD deubiq-
uitinates and inhibits Bcl-3 function in this 
newly discovered pathway.inhibitor of NF-κB). Degradation of 
IκB releases p50-p65 NF-κB dimers 
to activate target-gene transcription.
In the alternative pathway, the 
signal is strictly dependent on cer-
tain TNF family members and the 
intracellular signal is mediated by 
homodimers of IKK-α. This results 
in the subsequent liberation of 
NF-κB dimers (mostly p52/REL-B 
dimers) into the nucleus (Hayden 
and Ghosh, 2004) (Figure 1). A 
series of recent reports have shown 
that CYLD blocks signal transmis-
sion through the classical NF-κB 
cascade by deubiquitinating the 
TNF receptor-associated factor 2 
(TRAF2), TRAF6, and IKK-γ (NEMO) 
(Trompouki et al., 2003; Brum-
melkamp et al., 2003; Kovalenko et 
al., 2003). Notably, RNA interference 
of CYLD caused an increase in NF-
κB activation when the pathway was 
stimulated by phorbol 12-myristate 
13-acetate (PMA), CD40 ligands, 
or tumor necrosis factor α (TNF-α). 
Although these studies indicated 
that the CYLD deubiquitinating 
activity inhibits the NF-κB pathway, 
the regulatory mechanisms of CYLD 
catalytic activity and the physiologi-
cal function of CYLD in vivo have 
remained largely unknown.
In this issue of Cell, Massoumi 
and colleagues (2006) created 
Cyld-deficient mice and examined 
the effects of phorbol diester 12-
O-tetradecanoylphorbol 13-acetate 644 Cell 125, May 19, 2006 ©2006 Elsevi(TPA) and UV treatments on kerati-
nocytes. The phenotype observed 
in the Cyld-deficient mice—high 
sensitivity to skin tumor develop-
ment—mimics the pathogenesis of 
familial cylindromatosis. Further-
more, loss of CYLD in keratino-
cytes did not affect the transcription 
induced by the classical p65-p50 
NF-κB dimers but had clear effects 
on Bcl-3-linked p50- or p52-depen-
dent gene regulation. Bcl-3 acts as 
a nuclear coactivator that switches 
the transcriptional properties of 
NF-κB p50 and p52 homodimers 
from a repressive to an active state 
(Watanabe et al., 1997). The authors 
demonstrated that in normal kera-
tinocytes, TPA or UV light triggers 
the translocation of CYLD from the 
cytoplasm to the perinuclear region, 
where CYLD binds and deubiqui-
tinates Bcl-3, thereby preventing its 
nuclear accumulation. In Cyld-defi-
cient keratinocytes, Bcl-3 accumu-
lates in the nucleus, activates NF-κB 
by interacting with either p50 or p52, 
and induces transcription of NF-κB 
target genes such as cyclin D1. Nev-
ertheless, it is not fully understood 
at the molecular level how Lys63-
linked polyubiquitination of Bcl-3 is 
regulated and how this modification 
drives its nuclear translocation and 
interaction with the NF-κB p50 and 
p52 subunits in the nucleus. The 
components involved in recogni-
tion and translocation of Bcl-3 into er Inc.the nucleus will help to trace the 
upstream and downstream compo-
nents of this pathway.
What is clear from this study, how-
ever, is that the CYLD/Bcl-3 interac-
tion is not involved in the classical 
NF-κB pathway in keratinocytes. 
This leaves open the question of 
whether p50-Bcl-3 and p52-Bcl-3 
complexes are regulated via the NF-
κB alternative pathway or whether 
they form a new regulatory path-
way that is independent from both 
the classical and alternative path-
ways (Figure 1). To address these 
questions, it would be necessary 
to determine whether the alterna-
tive pathway is activated during skin 
tumor development. This can be 
addressed by examining the activa-
tion status of IKK proteins or their 
involvement in cyclin D1 regulation 
upon treatment with TPA or UV.
Further insights into the role of 
Bcl-3 in pathogenesis of cylindro-
matosis can be gained from analyz-
ing Bcl-3-deficient mice (Franzoso 
et al., 1997). These mice develop 
normally and reveal no gross mac-
roscopic abnormalities, but they 
show an impaired architecture in 
the spleen and lymph nodes and 
dysregulation of T and B cells 
functions. Whether the increased 
nuclear accumulation of Bcl-3 and 
the elevated occupation of the NF-
κB binding site of the cyclin D1 
promoter are indeed major factors 
responsible for the proliferation of 
Cyld-deficient keratinocytes can 
be examined in Bcl-3-deficient 
mice following TPA and UV stimu-
lation. The authors already indi-
cate such a possibility by showing 
that the depletion of Bcl-3 by small 
interfering RNA reduced cyclin D1 
promoter activation induced by 
TPA and reversed the increased 
proliferation rate of Cyld-deficient 
keratinocytes.
Interestingly, a recent report by 
Reiley et al. (2006) describes a new 
regulatory role for CYLD in T cell 
receptor (TCR) signaling. Cyld-defi-
cient mice are impaired in thymocyte 
development due to aberrations in 
the transition of double-positive to 
single-positive T cells. Contrary to 
the finding in keratinocytes, there are 
no defects in TNF-receptor-induced 
NF-κB signaling in bone-marrow-
derived macrophages of Cyld-defi-
cient mice. The fact that there are 
differences in CYLD function in thy-
mocytes and keratinocytes points to 
receptor-specific and cell-type-spe-
cific functions of CYLD. The regula-For many proteins associated with 
disease, their precise cellular func-
tion and their role in disease patho-
genesis remain unclear. One strat-
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In this issue of Cell, Lim et 
for inherited human ataxias,
cerebellar Purkinje cells. This
only share clinical and patho
and pathways in common.tion of CYLD deubiquitinating activity, 
which is not completely understood, 
awaits further experimental confirma-
tion in distinct cell types. At the same 
time, the understanding of keratino-
cyte-specific signaling mediated by 
CYLD provides a greater opportu-
nity to develop therapeutic agents 
for cylindromatosis. Potential agents 
include nonsteroidal anti-inflamma-
tory drugs (NSAIDs) such as aspirin 
and natural compounds (e.g., ginseng 
extract and green-tea extract), all of 
which can inhibit activation of NF-κB. 
These anti-inflammatory agents and 
CYLD have a similar effect on NF-κB 
signaling, even though they act on 
different targets in the pathway. Topi-
cal application of aspirin has already 
entered clinical trials for the treatment 
of cylindromatosis. It is worth testing 
whether aspirin’s efficacy in treating 
cylindromatosis depends on interfer-
ing with the Bcl-3 pathway as well. 
This study and the excitement in the 
field of NF-κB and cancer pathogen-
esis promise to foster the design of 
better therapeutics for cylindromato-
sis patients.Cell 125
egy to gain insight into the function 
of these proteins is to use the tools 
of systems biology to establish their 
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action networks. In this issue of Cell, 
Huda Zoghbi and colleagues report 
a protein-protein interaction network 
for the human cerebellar ataxias 
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